
8 November 2021
Plasma glial fibrillary acidic protein (GFAP) outperforms its cerebrospinal fluid (CSF) counterpart in the detection of amyloid-β (Aβ) pathology even in the early stages of Alzheimer’s disease (AD), indicates a cross-sectional study.